RE-BVS – Piemonte Repository

Sfoglia per AUTORE
GIORDANO D
Collezione AOU Città della Salute di Torino

Items : 10

Tildrakizumab and Quality of Life: Deep Dive into the Impact of Psoriasis and Treatment on Different Domains-Should Psychosocial Life Impairment Be Considered a Comorbidity? in Journal of clinical medicine / J Clin Med. 2025 Jan 2;14(1):223. doi: 10.3390/jcm14010223.

2025
ASL Torino 4
AOU Città della Salute di Torino
ASL Vercelli

Faure E; Papaianni V; Giordano D; Galdo G; Cerulli E; Zanetta R; Siliquini N; Solaroli C; Peila R; De Col E; Richetta AG; Dattola A; Stroppiana E; Giuffrida G; Castelli F; Di Brizzi EV; Licata G; Pertusi G; Uzzauto MT; Loconsole F; Zichichi L;

Non-invasive physiological assessment of intermediate coronary stenoses from plain angiography through artificial intelligence: the STARFLOW system. in European heart journal. Quality of care & clinical outcomes / Eur Heart J Qual Care Clin Outcomes. 2024 Oct 9:qcae024. doi: 10.1093/ehjqcco/qcae024.

2024
ASL Asti
ASL Città di Torino
AO Ordine Mauriziano
AOU Città della Salute di Torino

De Filippo O; Spampinato C; D'Ascenzo F; Giordano D; De Ferrari GM; Aldinucci M; Saglietto A; Burzotta F; Pawlus P; Boretto P; Musumeci G; Sinagra G; Capodanno D; Gallone G; Maremmani M; Wojakowski W; Varbella F; Gaibazzi N; Campo G; Giachet AT; Bruno F; Iannaccone M; Boccuzzi G; Fabris E; Tuttolomondo D; Quadri G; Franchin L; Palazzo S; Leone AM; et alii...

In pancreatic cancer patients, chemotherapy reshapes the gene expression profile and antigen receptor repertoire of T lymphocytes and enhances their effector response to tumor-associated antigens. in Frontiers in immunology / Front Immunol. 2024 Aug 8;15:1427424. doi: 10.3389/fimmu.2024.1427424. eCollection 2024.

2024
AOU Città della Salute di Torino

Cappello P; Giordano D; Campra D; Satolli MA; Spadi R; Genuardi E; Bonello L; Arigoni M; Calogero R; Curcio C; Bulfamante S; Brugiapaglia S; Cordero F; Novelli F;

Circulating autoantibodies to alpha-enolase (ENO1) and far upstream element-binding protein 1 (FUBP1) are negative prognostic factors for pancreatic cancer patient survival. in Clinical and experimental medicine / Clin Exp Med. 2023 Dec;23(8):5089-5100. doi: 10.1007/s10238-023-01236-5. Epub 2023 Nov 1.

2023
AOU Città della Salute di Torino

Curcio C; Rosso T; Brugiapaglia S; Guadagnin G; Giordano D; Castellino B; Satolli MA; Spadi R; Campra D; Moro F; Papotti MG; Bertero L; Cassoni P; De Angelis C; Langella S; Ferrero A; Armentano S; Bellotti G; Fenocchio E; Nuzzo A; Ciccone G; Novelli F;

IL17A critically shapes the transcriptional program of fibroblasts in pancreatic cancer and switches on their protumorigenic functions. in Proceedings of the National Academy of Sciences of the United States of America / Proc Natl Acad Sci U S A. 2021 Feb 9;118(6):e2020395118. doi: 10.1073/pnas.2020395118.

2021
AOU Città della Salute di Torino

Mucciolo G; Curcio C; Roux C; Li WY; Capello M; Curto R; Chiarle R; Giordano D; Satolli MA; Lawlor R; Scarpa A; Lukac P; Stakheev D; Provero P; Vannucci L; Mak TW; Novelli F; Cappello P;

In pancreatic cancer, chemotherapy increases antitumor responses to tumor-associated antigens and potentiates DNA vaccination. in Journal for immunotherapy of cancer / J Immunother Cancer. 2020 Oct;8(2):e001071. doi: 10.1136/jitc-2020-001071.

2020
AOU Città della Salute di Torino

Mandili G; Curcio C; Bulfamante S; Follia L; Ferrero G; Mazza E; Principe M; Cordero F; Satolli MA; Spadi R; Evangelista A; Giordano D; Viet D; Cappello P; Novelli F;

Immune-Complexome Analysis Identifies Immunoglobulin-Bound Biomarkers That Predict the Response to Chemotherapy of Pancreatic Cancer Patients. in Cancers / Cancers (Basel). 2020 Mar 21;12(3):746. doi: 10.3390/cancers12030746.

2020
AOU San Luigi di Orbassano
AOU Città della Salute di Torino

Hanash SM; Evangelista A; Satolli MA; Spadi R; Giordano D; Momin AA; Capello M; Hong W; Katayama H; Ferrero G; Follia L; Mandili G; Cordero F; Novelli F;

Integrative Analysis of Novel Metabolic Subtypes in Pancreatic Cancer Fosters New Prognostic Biomarkers. in Frontiers in oncology / Front Oncol. 2019 Feb 27;9:115. doi: 10.3389/fonc.2019.00115. eCollection 2019.

2019
AOU Città della Salute di Torino

Follia L; Ferrero G; Mandili G; Beccuti M; Giordano D; Spadi R; Satolli MA; Evangelista A; Katayama H; Hong W; Momin AA; Capello M; Hanash SM; Novelli F; Cordero F;

Anti-?-enolase antibody limits the invasion of myeloid-derived suppressor cells and attenuates their restraining effector T cell response. in Oncoimmunology / Oncoimmunology. 2015 Dec 21;5(5):e1112940. doi: 10.1080/2162402X.2015.1112940. eCollection 2016 May.

2016
AOU Città della Salute di Torino

Novelli F; Giordano D; Giovarelli M; Curto R; Cappello P; Tonoli E;

Intra-tumoral IFN-?-producing Th22 cells correlate with TNM staging and the worst outcomes in pancreatic cancer. in Clinical science (London, England : 1979) / Clin Sci (Lond). 2016 Feb;130(4):247-58. doi: 10.1042/CS20150437. Epub 2015 Nov 20.

2016
AOU Città della Salute di Torino

Novelli F; Prisco D; Bani D; Cianchi F; Coratti A; Satolli MA; Giordano D; Castiglione F; Ringressi MN; Pini A; Bencini L; Bechi P; Benagiano M; D'Elios MM; Ricci F; Rolla S; Niccolai E; Taddei A; Amedei A;